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ABSTRACT
In this study, we explored the existence of a tran-
scriptional network co-regulated by E2F7 and HIF1 ,
as we show that expression of E2F7, like HIF1 , is
induced in hypoxia, and because of the previously
reported ability of E2F7 to interact with HIF1 . Our
genome-wide analysis uncovers a transcriptional
network that is directly controlled by HIF1 and E2F7,
and demonstrates both stimulatory and repressive
functions of the HIF1 -E2F7 complex. Among this
network we reveal Neuropilin 1 (NRP1) as a HIF1-
E2F7 repressed gene. By performing in vitro and in
vivo reporter assays we demonstrate that the HIF1-
E2F7 mediated NRP1 repression depends on a 41
base pairs ‘E2F-binding site hub’, providing a molec-
ular mechanism for a previously unanticipated role
for HIF1 in transcriptional repression. To explore
the biological significance of this regulation we per-
formed in situ hybridizations and observed enhanced
nrp1a expression in spinal motorneurons (MN) of
zebrafish embryos, upon morpholino-inhibition of
e2f7/8 or hif1α. Consistent with the chemo-repellent
role of nrp1a, morpholino-inhibition of e2f7/8 or
hif1α caused MN truncations, which was rescued
in TALEN-induced nrp1ahu10012 mutants, and pheno-
copied in e2f7/8 mutant zebrafish. Therefore, we con-
clude that repression of NRP1 by the HIF1-E2F7
complex regulates MN axon guidance in vivo.
INTRODUCTION
Hypoxia (oxygen deprivation) is experienced by cells in fast
growing tissues such as embryos or solid tumors that out-
grow their vasculature or exhaust the local O2 pool. Tran-
scriptional adaptation to hypoxia is regulated by the het-
erodimeric, hypoxia-inducible transcription factors HIF1
and HIF2, which consist of an oxygen-degradable HIF,
and an oxygen-independent HIF subunit. The importance
of these factors for development is illustrated by the em-
bryonic lethality of mice lacking Hif1α, Hif2α or Hif1β
(1,2). In normoxia, HIF isoforms are constitutively de-
graded by the O2-dependent PHD/VHL pathway (3,4). Be-
low ∼5% O2, HIF levels stabilize according to the level
of hypoxia, resulting in functional HIF dimers that stimu-
late O2-homeostasis by inducing the expression of genes in-
volved in glycolysis, erythropoiesis and angiogenesis (3,4).
In mammals, the HIF-pathway is active over a wide physio-
logical range as embryonic development occurs at 3–5%O2,
and postnatal physiological oxygen levels range from 2–9%
O2 (1,2). On the other hand, HIF factors are also regulated
by O2-independent mechanisms leading to increased HIF
activity under normoxia. For example, normoxic HIF1 ac-
tivity can be enhanced by stimulation of HIF1α transcrip-
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tion as observed in macrophages or T cells (5), or by in-
creasedHIF1α translation, induced by theMAP kinase and
mTOR pathways downstream of growth factor signaling in
highly proliferative cells, or by augmented HIF1 protein
stabilization induced by heatshock protein 90 and calcium
signaling (3). These studies illustrate the versatile roles of
HIF factors in regulating gene expression, being activated
in response to a wide variety of stimuli.
The E2F family of transcription factors consists of eight
members that are classified as activators (E2F1–3) or re-
pressors E2Fs (E2F4–8). E2F7 and E2F8 (E2F7/8) are
termed atypical as they harbor 2 instead of 1 DNA-binding
domain and regulate transcription independent of DP pro-
teins (6). E2F7/8 have overlapping functions as E2f7 or
E2f8 deficient mice are viable and live to old age, while
E2f7/8 double knockout mice die around embryonic day
10.5 (7). The RB/E2F pathway is well known for its role
in cell cycle regulation, but recent studies demonstrate an
emerging role in control of physiological processes, indepen-
dent of its cell cycle functions, among which neuronal de-
velopment. Interestingly, telencephalon-specific retinoblas-
toma 1 (Rb1) deletion in mice showed a cell-autonomous
requirement for Rb1 in the migration of neuronal precur-
sor cells (8). This appeared to be mediated by E2F3, inde-
pendent of its ability to regulate proliferation, but through
direct transcriptional control of the atypical E2F target
neogenin (Neo1), a receptor for the netrin and repulsive
guidance molecule (RGM) families of chemotropic ligands
(9,10). In addition, the RB/E2F pathway also regulates
neuronal differentiation. E2F3 controls interneuron differ-
entiation in a cell cycle-independent manner upon retina-
specific deletion of Rb1 (11), while E2F7 represses the ex-
pression of the early differentiation genes Dlx1 and Dlx2
upon telencephalon-specific deletion of Rb1 involved in
neuronal differentiation in the brain (12). These data show
that E2F factors are able to regulate physiological processes
beyond their ability to control the cell cycle, but through the
regulation of atypical E2F target genes.
HIF and E2F factors are essential for development by
regulating distinct but also overlapping biological pro-
cesses (e.g. apoptosis, autophagy, cell cycle progression and
angiogenesis). Consistent with the notion that they have
been reported to also regulate gene expression by cooper-
ating with other transcription factors (6,13), we recently
found that E2F7/8 regulate transcription of VEGFA by
forming a complex with HIF1 (14). To investigate the
existence of a transcriptional network that is regulated
by this recently identified HIF1-E2F7/8 complex we per-
formed ChIP-sequencing (ChIP-seq) and microarray anal-
ysis. Our data not only identify a previously unknown
HIF1 and E2F7 co-regulated transcriptional network, but
also reveal a unanticipated role for HIF1 in transcrip-
tional repression, and discover an essential function for the
HIF1-E2F7 complex in regulatingmotor neuron guidance
through direct transcriptional control of NRP1 in vivo.
MATERIALS AND METHODS
Cell culture and hypoxia
The cervical cancer (HeLa) cell line was cultured in
DMEM (Invitrogen, 41966–052) supplemented with 10%
FBS (Lonza, DE14–802F) and 1% Penicillin/Streptomycin
(Lonza, DE17–602E). U2OS cells were cultured similarly.
For hypoxia treatment, cells were incubated in the H35 Hy-
poxystation (Don Whitley Scientific) at 1% O2 for 16 h.
Microarray gene expression analysis
The following samples were analyzed by microarrays: RNA
isolated from hypoxic HeLa cells transfected with either
control (scr), E2F7, E2F7 and E2F8, HIF1 or E2F7 and
HIF1 siRNAs (Figure 2A). Cells were harvested 48 h af-
ter transfection, and were grown the last 16 h in hypoxia.
RNA isolated from scr transfected, normoxic HeLa cells
was used common reference RNA. Within each group of
two biological replicates, sample versus common reference
hybridizations were performed in balanced dye-swap. Mi-
croarrays used were human whole genome gene expression
microarrays V1 (Agilent, Belgium) representing 34127 H.
sapiens 60-mer probes in a 4 × 44K layout. cDNA syn-
thesis, cRNA amplification, labeling, quantification, qual-
ity control and fragmentation were performed with an au-
tomated system (Caliper Life Sciences NV/SA, Belgium),
starting with 3 g total RNA from each sample, all as pre-
viously described (15). Microarray hybridization and wash-
ing was with a HS4800PRO system with QuadChambers
(Tecan, Benelux) using 1000 ng, 1–2% Cy5/Cy3 labeled
cRNA per channel as described (15). Slides were scanned
on an Agilent G2565BA scanner at 100% laser power, 30%
PMT. After automated data extraction using Imagene 8.0
(BioDiscovery), Loess normalization was performed (16)
on mean spot-intensities. Gene-specific dye bias was cor-
rected by a within-set estimate (17). Data were further ana-
lyzed by MAANOVA, modeling sample, array and dye ef-
fects in a fixed effect analysis. P-values were determined by
a permutation F2-test, in which residuals were shuffled 10
000 times globally. Gene probes with P < 0.05 after fam-
ily wise error correction (FWER) were considered signifi-
cantly changed. In cases of multiple probes per gene, the
values from the most 3′ probe were used. Selection of tar-
gets was based on both a significant P-value (<0.05) and
fold change cut-off of≥2 or≥1.5 (a cut-off m value of±1.0
or 0.585 (2log fold change), respectively), as indicated in the
text. Gene ontology analysis was performed using DAVID
andPANTHERgene ontology tools (18,19). Allmicroarray
gene expression data have been deposited in GEO (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66750).
siRNA transfection
HeLa cells were grown to confluence and re-seeded at
150 k/well (6 well plate, Greiner). Next day, cells were
siRNA transfected as specified by the manufacturer us-
ing 5 l/well RNAIMAX (Invitrogen, 13778–075) and a
final siRNA concentration of 50 nM. Medium was re-
placed the next day and cells were grown overnight in nor-
moxia or hypoxia and harvested 48 h after transfection.
For harvesting, cells were washed twice with cold PBS on
ice, scraped in cold PBS supplemented with protease in-
hibitors (Roche), and pelleted by centrifugation (2600×g ,
2 min at 4◦C). Protein samples were lyzed in 60 l of lysis-
buffer (0.05 M sodium phosphate pH7.3, 0.3MNaCl, 0.1%
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NP40, 10% Glycerol). Cell pellets for RNA isolation were
frozen in liquid nitrogen and stored in−80◦C. siRNAs used
in this study: hHIF1 (L-004018–00–0005, Thermo Sci-
entific), non-targeting siRNA #2 (D-001210–02, Thermo
Scientific), hARNT siRNA (L-007207–00–0005), hE2F7
(HSS135118, HSS135119, HSS175354, Invitrogen), hE2F8
(HHS128758, HSS128759, HSS128760, Invitrogen), Nega-
tive control medium (Invitrogen, 12935–300). The negative
control siRNAs from Thermo and Invitrogen were mixed
and used at a 1:1 ratio. For double transfection, half of the
amounts applied for the single siRNA transfections were
used, ensuring a final concentration of 50 nM. For siRNA
transfections in U2OS cells were seeded at a density of 100
k/well.
Statistical analysis
All statistical comparisons in this study were performed us-
ing a two tailed, independent t-test. Variances of two groups
were compared with an F-test. Differences were considered
significant with a P-value of <0.05.
Western blot analysis
Whole-cell lysates were prepared using a lysis buffer con-
taining 150 mM NaCl, 1.0% NP40, 0.5% deoxycholate,
0.1% SDS and 50 mM Tris (pH 8.0), supplemented
with Protease Inhibitor Cocktail (Roche). Protein lysates
were separated by SDS–polyacrylamide gel electrophore-
sis (PAGE) and transferred to a nitrocellulose mem-
brane. Membranes were probed with the following an-
tibodies: E2F7 (Santa Cruz, sc-66870), E2F8 (Abnova,
H00079733-M01; Abcam AB109596), HIF1 (BD Bio-
sciences, 610959), HDAC1 (sc-7872), E2F1 (sc-193),Mouse
IgG HRP-linked whole Ab (GE Healthcare, NA931), Rab-
bit IgG HRP-linked whole Ab (GE Healthcare, NA934).
As secondary antibodies, anti-rabbit-HRP (AmershamBio-
sciences, NA934; 1:5000) and anti-mouse-HRP (Amersham
Biosciences, NA931; 1:5000) were used. All antibodies were
diluted in 4% non-fat milk in TBST. Immuno-probed blots
were subjected to standard ECL reagents as described by
the manufacturer (GE Healthcare, RPN2106).
Chromatin immunoprecipitation (ChIP) and ChIP-
sequencing
ChIP was performed according the EZ ChIP protocol (Up-
state, 17–371) with the following specifications: HeLa cells
were seeded at day 1 at a concentration of 7 × 106 cells per
145 mm plate. Next day, cells were cultured overnight in
hypoxia, or continued to grow under normoxia, and har-
vested on day 3. For single and double ChIP, five 145 mm
plates were used per condition. In vitro crosslinking was
performed on a shaker at roomtemperature (RT) for 10
min, using 1% freshly made paraformaldehyde. Crosslink-
ing was quenched for 5 min incubation at RT on a shaker.
Next, cells were washed twice on ice with PBS (4◦C, sup-
plemented with protease inhibitors (11873580001, Roche)),
and harvested, pelleted and resuspended in 2 ml lysis buffer
(0.3% SDS, 10 mM EDTA, 50 mM Tris and protease in-
hibitors). Sonication (10 cycles of 10 s followed by 1 min
incubation on ice) was performed in a FACS tubes using
a Soniprep 150 sonicator (MSE). Ten microliters of soni-
cated sample was analyzed on gel to check for sonication ef-
ficiency. Sonicated lysates were centrifugated (10 min, 4◦C)
to remove insoluble components and large DNA fragments.
Two hundred microliters lysate was used per ChIP sam-
ple. The DNA concentration in the sonicated lysate was
measure using a Nanodrop to normalize the amount of in-
put DNA between normoxic and hypoxic ChIP samples.
Protein G agarose beads (16–266, Milipore) were coated
overnight in 0.1% BSA (Sigma, A3294), and 60 l was used
for pre-clear (2 h, 4◦C) and final precipitation of immune
complexes (1 h, 4◦C). For single ChIP, 5 g and for double
ChIP, 10 g was used. Immunorecipitation were performed
overnight at 4◦C on a rotating platform. In case of double
ChIP, eluates were diluted in dilution buffer and incubated
with another 10 g of antibody overnight. The following
antibodies were used: ChIP grade HIF1 (ab2185, Abcam)
E2F7 (sc-66870), E2F1 (sc-193), IgG (2729S; cell signaling).
De-crosslinked DNA was purified over a column (Qiagen,
28106) and eluted in 65 l H2O of which 2 l was used for
quantitative PCR. ChIP-sequencing was performed using
the double ChIP protocol with approximately 100 million
cells per sample. Lysates were sonicated for 7 min at max-
imum power on a Covaris S2 (Covaris). As ChIP-seq was
used as a qualitative assay for target identification, the ChIP
input material was not normalized. For validation of the
targets in subsequent quantitative ChIP-qPCR experiments
the input DNAwas normalized as explained above. Library
construction and sequencing were performed as described
previously (20). All raw ChIP-seq data have been deposited
in GEOwith the accession number GSE66956 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66956).
Luciferase reporter assay
U2OS cells were seeded at 100 k/well (6-well plate, Greiner)
and next day transfected (Superfect, Qiagen) following
manufacturer’s instructions. Per well (6 well plate) we used
2.5 g reporter plasmid, 100 ng TK renilla, and 25–500 ng
expression or control plasmid and 5 l Superfect. For com-
petition reporter assays, cells were transfected with 25 ng
of E2F1 expression together with 475 ng empty vector, or
475 ng E2F7 or HIF1 expression plasmid. After 6 h, the
medium was replaced and cells were cultured in hypoxia
or normoxia. Next day reporter activity was measured us-
ing the Dual-Luciferase Reporter Assay System (Promega,
E1910) on a microplate luminometer (Centro LB 960) 24
h after transfection. TK was used for normalization of the
data.
Zebrafish
All zebrafish strains were maintained in the Hubrecht In-
stitute (Utrecht Medical Center, The Netherlands) un-
der standard husbandry conditions. Animal experiments
were performed in accordance with the rules of the An-
imal Experimentation Committee of the Royal Nether-
lands Academy of Arts and Sciences (DEC). Transgenic
line used: Tg(nrp1a:gfp)js12Tg, (21) expressing gfp form a
∼7.5 kb (−7.5 kb up to 1st ATG) nrp1a promoter frag-
ment. Construction of TAL effector nucleases (TALENs):
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the TALEN-induced nrp1ahu10012 mutants, were generated
and genotyped similarly and along with the previously
published nrp1ahu9963 mutant, as previsouly described (22).
TALEN sequences were identified in nrp1a using TAL ef-
fector Nucleotide Targeter 2.0 (https://tale-nt-cac-cornell.
edu/) and chosen based on the location in the CUB do-
main and presence of an appropriate restriction enzyme site
(PvuII) for genotyping purposes. Embryos were staged (23).
Morpholino (MO)
The following published (14,24) morpholino (MO)
oligonucleotides (Genetools) were used: an E2f7
splice donor MO targeting exon 2–intron 2–3 (5′-
ATAAAGTACGATTATCCAAATGCAC-3′); an E2f8
splice donor MO targeting exon 2-intron 2–3 (5′-
CTCACAGGTATCCGAAAAAGTCATT-3′); a hif1ab
ATGMO (5′-CAGGAATGGATACTGGAGTTGTCAC-
3′); and a control MO (5′-CCTCTTACCTCAGTTACA
ATTTATA-3′). MO injections were performed using
zebrafish embryos up to the 2-cell stage.
Imaging
Imaging was performed on live embryos mounted in 0.5–
1% low melting point agarose (Invitrogen, 16520–050) dis-
solved in E3 buffer (5 mM NaCl, 0.17 mM KCl, 0.33 mM
CaCl2, 0.33 mMMgSO4), supplemented with Tricaine me-
sylate (MS222)) on a cell view cell culture dish (627860,
Greiner Bione). Imaging was performed with a Leica TCS
SPE-II confocal microscope (Leica Microsystems) using a
10 or 20x objectives with 1.5 digital zoom, Laser 488 nM
(7%), 600 Hz scan speed, frame average 4, format 1024 ×
1024, 8-bit images. For imaging after 24 hpf embryos were
raised in Phenylthiourea (PTU; Sigma). Imaging of gfp re-
porter expression in the eyes of Tg(nrp1a:gfp) fish was
performed using identical settings (gain, offset) for high,
medium and low classified embryos. Imaging and quantifi-
cation of MN defects was performed on the ∼10–11 MN
above the yolk sac extension.
In situ hybridization
In situ hybridization was performed as previously described
(25). Briefly, the nrp1a ISH probe was PCR-amplified form
zebrafish cDNA and cloned in the pGEM-T Easy vector
(Promega). For probe generation, 5 g of plasmid DNA
was linearized overnight at RT using NcoI (Thermo Scien-
tific). The linearized vector was excised from gel and pu-
rified using the QIAquick gel extraction kit as specified
by the manufacturer. DIG-labeled (11277073910, Roche)
RNA probes were generated by in vitro transcription using
SP6RNApolymerase (Promega) according to themanufac-
turer’s instructions. Vector DNA was removed by DNAse
treatment (Qiagen) at RT for 10 min after which RNA was
column purified (74106, Qiagen) and eluted in 30 l of
RNAse free MilliQ, supplemented with 1 l of RNAsin
(N2511, Promega). The RNA concentration was measured
on a NanoDrop 1000 (Thermo) and checked on agarose gel
after denaturation at 80◦C for 5 min.
RNA isolation, cDNA synthesis and quantitative PCR
Total RNA was extracted according to manufactur-
ers’ instructions using the RNeasy Mini Kit (Qiagen,
74106). cDNA was synthesized with random hexamer
primers according to manufacturers’ instructions (Fermen-
tas, K1622). An additional on-column DNase treatment
was performed using the RNAse-Free DNAse (79254; Qia-
gen). Quantitative PCR was performed on a MyiQ cycler
(Biorad) using SYBRgreen chemistry (Biorad). Gene ex-
pression was calculated using the Ct method adapted
for multiple-reference gene correction. In our in vitro stud-
ies two reference genes were used (ACTB, RPS18) and for
zebrafish samples three reference genes were used (TBP,
EF1α, β-Actin). MIQE standards were applied to our pro-
tocols (26). Oligonucleotides sequences use in this paper are
listed in Supplementary Table S1.
RESULTS
Hypoxia induces E2F7 expression through HIF1
To explore a potential transcriptional cooperation between
HIF and E2F factors we focused on HIF1 and E2F7/8, as
E2F7/8 were suggested to regulate a set of ‘hypoxia genes’,
as observed in E2f7/8 double knockout mice (7), and be-
cause of the recently reported interaction between E2F7/8
and HIF1 (14). Because HIF1 expression is regulated by
hypoxia, we first analyzed if E2F7/8 expression was also
regulated by hypoxia. E2F7/8 protein levels were examined
by Western blot analysis using lysates from HeLa cells cul-
tured under normoxia or hypoxia (16 h, 1% O2). This anal-
ysis showed that E2F7, but not E2F8 protein levels are in-
duced in hypoxia (Figure 1A). The specificity of the E2F7
and E2F8 immuno-staining was confirmed using HeLa cell
lysates transfected with three different siRNAs for E2F7
or E2F8 (Figure 1A). Throughout this study E2F7 siRNA
#3 and E2F8 siRNA #1–3 were used because of their ef-
ficient depletion of E2F7 and E2F8, respectively. To inves-
tigate if hypoxia regulates E2F7 expression on the mRNA
level, E2F7 mRNA levels were measured by quantitative
PCR (qPCR), using total RNA isolated from normoxic and
hypoxic HeLa cells. We found that E2F7, but not E2F8
mRNA levels are enhanced by hypoxia (Figure 1B). Treat-
ment of HeLa cells with the hypoxia-mimetic agent desfer-
rioxamine (DFO) also induced E2F7 protein and mRNA
levels (Supplementary Figure S1A, B). The induction of
E2F7 expression by hypoxia and DFO was also shown in
U2OS cells (Supplementary Figure S1C–E), suggesting a
general mechanism. Because HIF proteins are key regula-
tors of the transcriptional response to hypoxia, we hypoth-
esized a role for HIF in stimulating E2F7 transcription in
hypoxia. Indeed, analysis of the E2F7 promoter (Supple-
mentary Figure S1F) revealed the presence of multiple pu-
tative HIF-binding sites (HIF-BS), to which HIF1 binding
was confirmed using ChIP assays (Figure 1C, Supplemen-
tary Figure S1G). Binding of E2F1 to the E2F7 promoter
served as a positive control (14). To test if HIF1 also stim-
ulates E2F7 transcription in hypoxia, E2F7 mRNA levels
were determined inHIF1 depleted or control cells. Knock-
down (KD) of HIF1 by siRNA abolished the hypoxic in-
duction of E2F7 mRNA and protein in HeLa (Figure 1D)
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Figure 1. E2F7 expression is induced in response to hypoxia by HIF1. (A) Westernblot analysis of E2F7, E2F8 andHIF1 expression in lysates fromHeLa
cells transfected with control (scrambled, scr) siRNA, or one of three different E2F7 or E2F8-specific siRNAs (numbered 1, 2 and 3), as indicated. Cells
were maintained in normoxia (−) or hypoxia (+) as indicated. Non-specific and background (‘b’) bands serve as loading controls. (B) Graphs showing
E2F7, E2F8 or VEGFA mRNA levels (depicted as fold change compared to normoxic mRNA levels) isolated from HeLa cells grown in normoxia or
hypoxia, and determined by qPCR. In this and all subsequent figures black bars present normoxic (N), and white bars hypoxic (H) conditions. (C) ChIP
assay, using normoxic or hypoxic HeLa cells, showing enrichment of HIF1, E2F1 (positive control) or IgG (negative control) on the E2F7 promoter
(element 2). (D) Graphs showing E2F7 or E2F8mRNA levels as determined by qPCR. RNA was isolated from HeLa cells grown in normoxia or hypoxia,
transfected with control (scr) or HIF1 siRNA as indicated. Lower panels are Western blots showing E2F7, HIF1 and HDAC1 (loading) protein levels.
All quantified data present the average ± S.D. compared to the indicated controls in at least three independent experiments.
and U2OS cells (Supplementary Figure S1H). From these
data we conclude that hypoxia stimulates E2F7 expression
through direct promoter activation by HIF1.
Identification of HIF1-E2F7 target genes by genome-wide
analysis
To investigate if the hypoxia-induced factors HIF1 and
E2F7 co-regulate a transcriptional network, ChIP-seq and
microarray experiments were conducted. As outlined in
Figure 2A, ChIP-seq was performed for E2F7 using nor-
moxic or hypoxic HeLa cells, while HIF1 ChIP-seq exper-
iments were only performed using HeLa cells cultured in
hypoxia. ChIP-seq for E2F7 revealed 3761 and 2682 tar-
get genes in normoxia and hypoxia, respectively, of which
the majority (2381) are bound by E2F7 under both condi-
tions (Supplementary Figure S2A, Supplementary data set
S1). The observed slight reduction of the number of E2F7
targets in hypoxia likely results from lower amounts of in-
put DNA as hypoxia reduces the proliferation of the cells,
demonstrated by an average cell number reduction of 24.3%
in six independent experiments. The HIF1 ChIP-seq re-
vealed 11666 HIF1 targets of which 2258 overlap with the
identified E2F7 targets (Supplementary Figure S2A). Ap-
proximately 60–65% of the E2F7, and 30% of the HIF1
peaks are located within 1000 base pairs (bp) from an an-
notated transcriptional start sites, and both E2F and HIF
DNA binding motifs were significantly enriched in E2F7
andHIF1 peaks, respectively (Supplementary Figure S2B,
Supplementary data set S2). Notably, gene-ontology anal-
ysis (Supplementary data set S3) revealed many signifi-
cantly HIF1 and E2F7 co-regulated biological processes
(among which cell cycle, DNA replication and nucleoside,
nucleotide and nucleic acid metabolism). Examples of over-
lapping peaks of common HIF1 and E2F7 bound targets
are shown in Supplementary Figure S3A. ChIP-seq analysis
also confirmed E2F7 as a HIF1 target (not shown).
Microarray analysis was next performed (in duplicate, us-
ing biological replicates) to analyze which of the bound tar-
gets are also regulated by HIF1 and E2F7. As we previ-
ously noted that depletion of E2F7 in hypoxia derepresses
E2F8 expression (14), through which E2F8 may compen-
sate for the loss of E2F7 (7), we not only analyzed gene
expression in E2F7 depleted cells, but also in E2F7/8 de-
pleted cells. To analyze a possible synergistic cooperation
between E2F7 andHIF1we also simultaneously knocked-
down these proteins. In addition to these conditions, RNA
was also isolated from hypoxic HeLa cells transfected with
a control or HIF1 siRNA (Figure 2A). For the identifi-
cation of E2F7 and HIF1 common targets described be-
low we used the microarray data set from the E2F7/8 de-
pleted cells, although the E2F7 microarray data set in gen-
eral yielded the same results (as will be discussed below).
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Upregulated fc P PPvalue fc value fc  value fc  value
PLSCR4 4.59 0.000 6.38 0.000 7.74 0.000 6.95 0.000
EDEM3 3.75 0.001 2.54 0.000 2.68 0.000 3.14 0.018
SECTM1 2.99 0.000 2.84 0.000 2.65 0.000 3.78 0.000
NRP1 2.80 0.000 2.41 0.002 2.37 0.000 2.45 0.006
LBR 2.67 0.001 2.00 0.005 2.10 0.002 2.28 0.025
SYPL1 2.49 0.000 2.30 0.000 2.41 0.000 2.57 0.002
SETD7 2.49 0.001 3.43 0.000 3.21 0.000 2.76 0.004
C8orf83 2.48 0.006 2.51 0.003 2.50 0.001 2.30 0.009
CYP1B1 2.40 0.000 2.29 0.004 2.13 0.000 2.51 0.001
TGOLN2 2.33 0.001 2.37 0.004 2.51 0.001 2.34 0.010
C4orf34 2.27 0.001 2.57 0.000 2.72 0.000 2.31 0.008
MTAP 2.21 0.002 2.56 0.000 2.26 0.000 2.42 0.012
IMPA2 2.20 0.000 2.81 0.000 2.92 0.000 2.67 0.000
TMX1 2.03 0.001 2.57 0.001 2.49 0.000 2.10 0.014
downregulated
CYR61 4.43 0.000 10.50 0.000 12.01 0.000 8.17 0.000
DDAH1 2.46 0.000 2.44 0.000 2.54 0.000 2.73 0.001
GABARAPL3 2.14 0.001 2.43 0.000 2.38 0.000 2.34 0.009
ATF3 2.09 0.008 2.60 0.001 2.26 0.000 2.37 0.002
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E2F7 ChIP-seq 60 (25%) 41 19
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Figure 2. Genome-wide analysis of HIF1 and E2F7 common targets by ChIP-seq and microarray analysis. (A) Flow chart showing the applied approach.
The E2F7 ChIP-seq was performed both in normoxia (N) and hypoxia (H), all other experiments only in hypoxia. (B) Table that summarizes the overlap
between the E2F7 and HIF1 targets identified in the microarray data (cut off:≥ 2 fc; P< 0.05) and ChIP-seq. The E2F7 ChIP-seq experiment performed
on hypoxicHeLa cells lysates was used for this analysis. Numbers between parentheses present the% overlap of themicroarray andChIP-seq data. Numbers
of genes identified are separated in up- and down-regulated genes. (C) Venn diagram showing the overlap between HIF1 (149) and E2F7/8 (60) directly
regulated targets, separated in up- and down-regulated genes. (D) Table showing 18 novel common direct and regulated (≥2 fc; P< 0.05) targets of HIF1
and E2F7/8. Numbers present fold up- or down-regulation of mRNA levels in the indicated conditions compared to controls, and associated P-values.
HIF1-E2F7 repressed genes are shown in green, activated genes in red.
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Using a stringent threshold of ≥2-fold change and a P-
value of <0.05, microarray analysis identified 240 E2F7/8,
and 181 HIF1 regulated genes (Figure 2B). Sixty out of
these 240 E2F7/8 regulated genes were also identified by
E2F7 ChIP-seq, whereas 149 out of 181 HIF1 regulated
genes were also identified by HIF1 ChIP-seq (Figure 2B).
The overlap between the 60 E2F7, and 149 HIF1 direct
and regulated genes revealed 18 common HIF1-E2F7 tar-
gets of which fourteen are repressed and four are stimu-
lated (Figure 2C,D). Similar analysis, now using a microar-
ray threshold of≥1.5-fold change (and a P-value of<0.05),
revealed 56 direct and regulated HIF1-E2F7 targets, of
which 37 are repressed and 17 are activated (Supplemen-
tary Figure S2D–F). The fact that almost all of these com-
mon targets are not differentially regulated by E2F7/8 and
HIF1, irrespective of their opposite roles in gene regu-
lation, strongly suggests that they are regulated by a sin-
gle HIF1-E2F7 complex and are not independent acts
of two transcription factors on the same set of promot-
ers. This is also underscored by an almost complete lack
of differentially regulated HIF1 and E2F7/8 targets in
the microarray data (Supplementary Figure S2C–D). The
microarray analysis also demonstrates a predominant role
for E2F7 in gene regulation in hypoxia, as the 18 novel
HIF1-E2F7 targets were comparably regulated between
E2F7 and E2F7/8 depleted cells (Figure 2D), and because
siRNA-knockdown of E2F7 or E2F7/8 not only resulted
in a comparable number of deregulated genes (980 versus
951, respectively (cut-off ≥ 1.5; P < 0.05), Supplementary
Figure S2E), but also in a significant overlap (76% of the
genes identified in the siE2F7/8 microarrays are also iden-
tified in the siE2F7 microarrays, S4 Data set). In addition
we show that inactivation of one component of the HIF1-
E2F7 complex is sufficient to disable its function, and that
no synergistic gene regulatory effects are observed in E2F7
and HIF1 co-depleted cells (Figure 2D). Together these
data demonstrate the existence of a HIF1 and E2F7 reg-
ulated transcriptional network in which the HIF1-E2F7
complex can function as a repressor or activator.
The transcriptional repressive activity of the HIF1-E2F7
complex is enhanced in hypoxia
To investigate the binding of the HIF1-E2F7 complex to
the 18 common targets (Figure 2D) in normoxia and hy-
poxia, we performed ChIP-qPCR assays. To correct for the
reduced proliferation in hypoxia, ChIP lysates were nor-
malized for the amount of input DNA. Multiple indepen-
dent E2F7 ChIP-qPCR assays confirmed E2F7 binding to
the common targets and demonstrated that E2F7 binding
is comparable between normoxia and hypoxia, although
binding to NRP1 (Figure 4B), MTAP, LBR (Figure 3A)
and ATF3 (Figure 3C) was slightly enhanced in hypoxia.
E2F7 binding to a previous reported E2F site in the E2F1
promoter served as a positive control (14), whereas no E2F7
binding was detected to a non-specific region 700 bp up-
stream of this site, showing a ChIP-resolution of <700 bp
(Figure 3E). HIF1 binding was also confirmed to all com-
mon target promoters, showing enhanced enrichment in hy-
poxia (Figures 3A, C and 4B).
As E2F7 inhibits transcription upon binding to E2F-
binding sites (BS) (20) and HIF activates transcription
when acting through HIF-BS (27,28) we hypothesized that
the HIF1-E2F7 complex regulates the repressed targets
via E2F-BS, through which E2F7 may engage HIF1 in
transcriptional repression. This hypothesis predicts that
other E2F family members may also bind the promoters
of HIF1-E2F7 repressed targets. We tested this hypoth-
esis for E2F1, by performing ChIP-qPCR. These experi-
ments demonstrate that E2F1 binds the NRP1 (Figure 4B)
and all other common repressed target promoters both in
normoxia and hypoxia, although binding was significantly
diminished in hypoxia (Figure 3A). As hypoxia increased
HIF1, but decreased E2F1 binding to the common targets,
these data suggest that HIF1 might compete with E2F1 for
promoter binding in hypoxia.
To explore the expression of the common targets in nor-
moxia and hypoxia, we performed siRNA-qPCR experi-
ments. Compared to control transfected cells, siRNA ab-
lation of either E2F7/8, E2F7, HIF1 or HIF1 and E2F7
verified the repressive (Figures 3B and 4D, Supplementary
Figure S4A) or stimulatory (Figure 3D) regulation of the
targets by HIF1-E2F7. The predominant role of E2F7
over E2F8 in regulating gene expression in hypoxia was also
confirmed, as knockdown of E2F7 alone resulted in a com-
parable response compared to E2F7/8 depleted cells (Fig-
ures 3B, D and 4D, E). For IMPA2 and GABARAPL3 no
qPCR protocols could be designed meeting MIQE stan-
dards (26). The E2F7 repressed target E2F1 (7,29), and
the HIF1 stimulated target NIX served as positive controls,
confirming functional E2F7 and HIF1 KD, respectively
(Figure 4E). By comparing the normoxic and hypoxic ex-
pression of the common targets we noted that 9 out of 13
of the HIF1-E2F7 repressed targets are downregulated in
hypoxia (Figure 3B), consistent with the hypoxic induction
of E2F7 and HIF1. In addition, 12 out of 13 repressed
HIF1-E2F7 targets were more significantly repressed by
the complex in hypoxia compared to normoxia (Figures 3B
and 4D, Supplementary Figure S4A). For example, com-
pared to their condition specific controls, KD of E2F7/8 in
hypoxia resulted in a higher NRP1 derepression (∼5-fold)
than E2F7/8 KD in normoxia (∼3-fold, Figure 4D). To-
gether these data confirm the binding and regulation of the
common targets by HIF1 and E2F7, and show that the in-
creased expression of E2F7 (and HIF1) in hypoxia results
in enhanced repression of the common repressed targets un-
der these conditions.
Because HIF1 is primarily known as part of the HIF1
transcription complex, in which HIF1 cooperates with
HIF1/ARNT (3,4), and because we recently demon-
strated that E2F7 binds to the N-terminal 80 amino acids
of HIF1, a region to which ARNT also binds (14), we hy-
pothesized that ARNT could be part of the HIF1-E2F7
complex. To test this we knocked down ARNT in nor-
moxic and hypoxic HeLa cells using siRNA, after which
HIF1-E2F7 common target gene expression was analyzed
by qPCR. Efficient siRNA knockdown of ARNT (Supple-
mentary Figure S4B) resulted in the expected reduced hy-
poxic induction of the known HIF1 targets PGK1 andNIX
(Supplementary Figure S4C). Interestingly, ARNT differ-
entially affected expression of the common target genes.
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Figure 3. Binding and regulation of the common targets by the HIF1 and E2F7. (A) Graphs show ChIP-qPCR analysis of E2F7 (left panels), HIF1
(middle panels) and E2F1 (right panels) enrichment on the common repressed target promoters. Non-specific, isotype matched IgG serve as a negative
control. (B) Graphs showing mRNA levels as determined by qPCR and presented as fold change comparing to scr normoxia, of the common repressed
targets.Messenger RNA levels were analyzed in HeLa cells transfected with control (scr), E2F7 and E2F8 (7/8), E2F7 (7), HIF1 (1) or E2F7 andHIF1
(7/1) siRNAs and grown in normoxia or hypoxia, as indicated. (C) Similar as in (A) but now for the HIF1-E2F7 induced targets. (D) Similar as in (B)
but now for the HIF1-E2F7 induced targets. (E). Upper graphs present E2F7 binding to the E2F1 promoter, to a control region (in the E2F1 promoter)
and the E2F3 promoter. Lower graphs show E2F7, HIF1 and E2F1 enrichment to theMCM2 promoter. All quantified data present the average ± S.D.
compared to the indicated controls in at least three independent experiments.
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Figure 4. In vitro and in vivo validation ofNRP1 regulation by HIF1 and E2F7. (A) ChIP-seq signal (y-axis: peak height) shown for E2F7 (N and HYP)
and HIF1 (HYP) on the NRP1 promoter (indicated in grey). Input DNA was sequenced as a control. Lines underneath the graphs indicate annotated
genes, boxes present exons and lines with arrows indicate introns. Arrow indicates direction of transcription. (B) Validation of HIF1, E2F7 and E2F1
enrichment on the NRP1 promoter as analyzed by ChIP-qPCR in normoxic or hypoxic HeLa cells. Isotype matched IgG served as a negative control. (C)
Positive controls for ChIP: binding of E2F7 to the E2F1 promoter, and HIF1 binding to the BNIP3L promoter. A non-specific region 700 bp upstream of
the E2F binding site in the E2F1 promoter served as a negative control. (D) Graph shows NRP1 mRNA levels as determined by qPCR in lysates isolated
from HeLa cells transfected with control (scr), E2F7 and E2F8 (7/8), E2F7 (7), HIF1 (1) or E2F7 and HIF1 (7/1). (E) Same as (D) but now for
E2F1 and NIX mRNA levels, positive controls for E2F7 and HIF1, respectively. (F) In situ hybridizations (ISH) for nrp1a using non-injected control
(NIC), e2f7/8 MO (5 + 5 ng, n = 46), or hif1ab MO (5 ng, n = 70) injected zebrafish embryos, obtained from three independent experiments. e2f7/8 MO
and NIC littermates were analyzed at 26 hpf, hif1ab MO injected and NIC littermate embryos at 28 hpf. 100% of the e2f7/8 MO injected embryos, and
69% of the hif1ab MO injected embryos showed enhanced nrp1a expression in MN. All panels show lateral views. Panels 2, 3, 7 and 8 show magnifications
of the head region. Panels 4, 5, 9 and 10 show magnifications of the trunk region. Asterisks show examples of spinal motorneurons. (G) Graphs show fold
change of epo or e2f1mRNA expression in hif1ab MO (1) or e2f7/8 (7/8) injected zebrafish embyros, respectively, compared to NIC. mRNA levels were
determined in >30 embryos from three independent experiments. All quantified data present the average ± S.D. compared to the indicated controls in at
least three independent experiments.
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Knockdown of ARNT (and HIF1) derepressed NRP1,
and reduced CYR61 mRNA expression (Supplementary
Figure S4C), similar to the HIF1 and E2F7 regulation of
these genes (Figures 3D and 4D), while the HIF1-E2F7
repressed targets CYP1B1 and PLSCR4 (Figure 3B) were
not affected (Supplementary Figure S4C). These data sug-
gest a differential requirement for ARNT in HIF1-E2F7
target gene regulation.
The HIF1-E2F7 complex represses NRP1 during zebrafish
development
To examine if the HIF1-E2F7 complex also regulates its
targets in vivo, we selected Neuropilin 1 (NRP1) for further
analysis, as the emerging role of E2Fs in neuronal develop-
ment (see introduction) could involve transcriptional con-
trol of NRP1. NRP1 is a non-tyrosine kinase transmem-
brane receptor that was originally identified in the Xeno-
pus nervous system (30). Gene knock-out studies in mice
showed an essential role for this receptor in neuronal (and
vascular) development (31–33). In neuronal development,
NRP1 functions in a holoreceptor complex with plexins,
serving as the main receptor for class III semaphorin 3A
(SEMA3A) (33,34). Binding of SEMA3A to the NRP1
receptor complex results in growth cone collapse and re-
pulsive axon guidance signals (35,36), as displayed by tar-
get overshooting of cranial and spinal nerves in Nrp1 or
Sema3a knockout mice (31,37), which can ultimately also
lead to neuronal cell death (38,39).
Because nrp1a mRNA expression can efficiently be de-
tected by in situ hybridization (ISH) during zebrafish devel-
opment (40), and established zebrafishMO directed against
e2f7/8 (14) or hif1α mRNA (24) are available, we used this
model system to verify the regulation of NRP1 by HIF1-
E2F7/8 in vivo. As it was recently shown that MO-induced
phenotypes are not necessarily recapitulated in correspond-
ing genetic mutants (22), it is important to note that the
specificity of the e2f7/8MO and hif1α MO was extensively
tested. The e2f7/8 splice site MO were demonstrated to in-
terfere with e2f7/8mRNA splicing, resulting in the deregu-
lation of classic e2f7/8 target genes in vivo (14). In addition,
angiogenic defects induced by these e2f7/8 MO were res-
cued upon co-injection of wild-type mRNA, and were phe-
nocopied in corresponding e2f7/8 mutant zebrafish (14).
Comparably, the hif1α ATG-MO effectively blocked hif1
translation, and inhibited hif1 target genes expression in
vivo, while its effects on neural crest development could be
rescued upon co-injection of wild-type hif1a mRNA (24).
Whether hif1 morphants phenocopy hif1 mutants is un-
known as these mutants are currently unavailable. Together,
these experiments validate the use of theseMO to character-
ize the regulation of NRP1 by E2F7/8 and HIF1 during
zebrafish development.
To investigate this, zebrafish embryos were injected with
e2f7/8 MO or hif1α MO, after which nrp1a mRNA levels
were analyzed at day 1 post fertilization (dpf) by ISH. MO
inhibition of endogenous e2f7/8 resulted in increased nrp1a
mRNA levels compared to non-injected control embryos
(NIC), displayed by enhanced expression in the head re-
gion (Figure 4F, panel 1–3) and in the trunk motorneurons
(MN) (Figure 4F, panel 1,4,5). Similarly, MO inhibition of
endogenous hif1 also enhanced nrp1a expression in the head
and trunk MN (Figure 4F). Consistent, with the previous
studies (14,24), MO depletion of e2f7/8 derepressed expres-
sion of its classical targets e2f1 expression, while inhibition
of hif1 reduced expression of its classical target epo, in-
dicating the functional MO inhibition of e2f7/8 and hif1
(Figure 4G). These data show that e2f7/8 and hif1 repress
nrp1a during zebrafish development.
We also tested if hypoxia repressed nrp1a and nrp1b ex-
pression in zebrafish. Similar to hypoxic NRP1 mRNA re-
pression in HeLa and U2OS cells, hypoxia significantly re-
pressed nrp1a and nrp1bmRNA expression in zebrafish em-
bryos (Supplementary Figure S5A). The hif1 target gene
phd3 (41) served as a hypoxia marker. Interestingly, MO-
inhibition of hif1a significantly derepressed hypoxic nrp1a
and nrp1b expression (Supplementary Figure S5B), while
MO-inhibition of e2f7/8 also derepressed hypoxic nrp1a
and nrp1b expression, although to a non-significant level.
These data suggest an evolutionary conserved hypoxic reg-
ulation of NRP1 by the HIF1-E2F7 complex.
The HIF1-E2F7 complex represses NRP1 expression
through an E2F-hub
To investigate mechanistically how the HIF1-E2F7 re-
pressesNRP1 expression, we first performed in vivo reporter
assays using Tg(nrp1a:gfp)js12 reporter fish (21), in which
gfp is expressed from a 7.5 kb nrp1a promoter fragment
displaying gfp expression in multiple tissues, including the
retina. A Tg(nrp1a:gfp)js12 line was used exhibiting low
transgene copy numbers, resulting in embryos having vari-
able retinal gfp expression, classified as high, medium or
low (Figure 5A). Compared to injection of control MO, in-
jection of e2f7/8 MO or hif1 MO significantly enhanced
retinal gfp expression compared to controlMO injected fish
both at 1 and 2 dpf (Figure 5A). Consistently, the number
of fish with low retinal gfp expression were decreased upon
MO-depletion of e2f7/8 or hif1 (Figure 5A). These data
demonstrate that e2f7/8 and hif1 repress the nrp1a pro-
moter in vivo.
To examine the promoter regulation in more detail, a
1532-human NRP1 (-1984/-453) promoter fragment was
cloned encompassing the E2F7 and HIF1 binding peaks
(Figure 4A, grey box). Based on available restriction sites,
three other fragments were subcloned from this fragment
(Figure 5B). These promoter fragments were used to further
explore the regulation of the NRP1 promoter using in vitro
reporter assays. As we found that E2F1 binds the NRP1
promoter, and we hypothesized that the E2F7-HIF1 com-
plex may particularly inhibit E2F1-induced NRP1 pro-
moter activation (judging from the differential E2F1 and
HIF1 binding to the common repressed targets, Figures
3A and 4B), we first analyzed the ability of E2F1 to in-
duce the NRP1 promoter fragments. Overexpression of
E2F1 equally induced the 1532, 982 and 246 NRP1 pro-
moter fragments, but not the 550-bp fragment (Figure 5C),
demonstrating the E2F-responsiveness of the NRP1 pro-
moter is contained in the 246-fragment. Notably, the pub-
lished E2F1-responsive promoters E2F1 and E2F7 were in-
duced 20-fold and 8-fold, respectively (Figure 5D), while
the NRP1 246 fragment was induced 300-fold, showing the
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Figure 5. The HIF1-E2F7 complex regulates NRP1 through an E2F-hub. (A) Left panels show confocal images of the head region of Tg(nrp1a:gfp)js12
zebrafish at 28 and 52 hpf. Fish are divided in three groups (high, medium, low) based on the level of transgene expression in the eye (showing 2 examples
per group). Graphs present quantification of the three groups at the indicated times after injection of control MO, e2f7/8 MO (5 + 5 ng) or hif1MO (5
ng) in zebrafish embryos (n ≥ 154 embryos in ≥4 independent experiments for each specific condition). (B) Schematic figure of the cloned 1532 bp human
NRP1 promoter, and promoter regions subcloned from it, using NcoI and SacI restriction sites. (C) Luciferase reporter assays showing the fold induction
of normalized relative luciferase units (NRLU) of differentNRP1 promoter constructs by E2F1 compared to controls. (D) Similar as in (C) but now for the
E2F1 control promoters E2F7 and E2F1. (E) Reporter assay showing the dose-dependent induction of the NRP1 promoter activity by different amounts
of E2F1. (F) Reporter assay comparing the activity of the indicated NRP1 promoter constructs in hypoxia compared normoxia. (G) Representation of
the 246 bp NRP1 promoter and putative E2F binding sites as identified by MatInspector. HIF binding sites were not identified in the 246 bp fragment.
(H) Reporter assay showing activity of the 1532 bp NRP1 promoter in the presence of E2F1 alone (set at 100%) or together with E2F7 or HIF1 (1). (I)
Control reporter assays showing regulation of the E2F7 promoter (left panel) promoter in the presence of E2F1 alone (set at 100%), or together with E2F7.
Middle and right panels show positive controls to check for functional E2F7 or HIF1 activity using E2F1 or VEGFA promoter constructs respectively. (J)
Reporter assay showing induction of the wild-type and the E2F-hub NRP1 promoter by E2F1 compared to controls. (K) Similar as in (H) but now for
the wildtype or 41 bp E2F-hub deleted (E2F) 246 bp NRP1 promoter. All quantified data present the average ± S.D. (except for (A) in which the average
± S.E.M. as shown) compared to the indicated controls in at least three independent experiments.
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highly E2F-responsiveness of this promoter. Ectopic E2F1
induced the NRP1 promoter in a dose dependent man-
ner both in normoxia and hypoxia (Figure 5E). Consis-
tent with the down-regulation of NRP1 mRNA levels in
hypoxia (Figure 3D), hypoxia also down-regulated the 246
bpNRP1 promoter (Figure 5F). Notably, E2F7 andHIF1
repressed E2F1-induced NRP1 promoter activation (set at
100%) by 80% or 55%, respectively (Figure 5H). As positive
controls, E2F7 repressed E2F1-induced E2F7 promoter ac-
tivity, whereas expression of E2F7 or HIF1 alone, repressed
the E2F7, or activated the VEGFA promoter, respectively
(Figure 5I).
To explore through which motifs NRP1 is regulated by
HIF1-E2F7, the 246-bp fragment was analyzed for the
presence ofHIF- andE2F-BS usingMatInspector software.
This revealed the presence of multiple putative E2F, but no
putative HIF-BS (Figure 5G). Deletion of a 41 bp region
containing 5 closely located, putative E2F-BS (hereafter re-
ferred to as ‘E2F-binding site hub’ (E2F-hub)) reduced the
ability of E2F1 to stimulate the NRP1 promoter by 80%
(Figure 5J). Notably, the capacity of E2F7 andHIF1 to re-
press the E2F1-induction of theNRP1 promoter was signif-
icantly impaired in the E2F-hub mutant promoter (Fig-
ure 5K). In conclusion, these data show that the HIF1-
E2F7 complex inhibits NRP1 promoter activation through
an E2F-hub.
The HIF1-E2F7 complex regulates axon guidance of spinal
motorneurons through NRP1
Because NRP1 functions in a holoreceptor complex
with plexins, serving as the main receptor for SEMA3A
in neuronal development (33,34), transducing repulsive
axon guidance signals (35,36), we next explored if the
HIF-E2F7 complex may regulate MN axon guidance
through regulation of NRP1. To this end, we injected
Tg(nrp1a:gfp)js12 zebrafish with e2f7/8 MO, hif1α MO or
control MO after which ventral MN projections were ana-
lyzed in the trunk at 2 dpf. Interestingly, while injection of a
control MO (10 ng) did not affect the formation of caudal
primary MN, injection of e2f7/8 MO (5 ng each) or hif1α
MO (5 ng) significantly affected MN guidance, resulting in
MN truncation in approximately 25% of all MN analyzed
(Figure 6A, B).
To investigate if E2F7/8 and HIF1 regulate MN guid-
ance through NRP1, we performed similar experiments in
a TALEN-induced nrp1ahu10012 mutants, which were gen-
erated similarly and along with the previously published
nrp1ahu9963 mutant, and result in an identically truncated
protein (Supplementary Figure S6A) (22). Similar to the
previously published nrp1ahu9963 mutant, nrp1ahu10012 mu-
tant zebrafish are viable and do not display vascular de-
fects (22). Analysis of ventral MN in nrp1ahu10012 mutant
zebrafish did not reveal MN defects around 2 dpf (Figure
6A, left panels), showing that loss of nrp1a itself is not es-
sential for MN axon guidance. These data are in contrast
with the essential function of Nrp1 in neuronal develop-
ment in mice (31,32), and suggest that nrp1b may com-
pensate for the loss of nrp1a in zebrafish. Besides this, in
our experiments, MO-depletion of hif1 or e2f/8 results in-
stead in significantly enhanced nrp1a expression, suggesting
that the chemo-repulsive action of nrp1a must not exceed
a certain threshold in order for MN development to pro-
ceed normally. Apparently, the HIF1-E2F7 complex is re-
quired to limitNRP1 expression in this process. In line with
our observations, ectopic sema3 levels also causes truncated
(or missing) ventral motorneurons during zebrafish devel-
opment (21,42).
Interestingly, MN defects induced by injection of e2f7/8
MO or hif1 MO, were reduced by 50% in nrp1ahu10012
mutant zebrafish (Figure 6A and B), demonstrating that
ablation of hif1 or e2f7/8 causes MN truncation, at
least partially in a nrp1a dependent manner, and that the
chemo-repulsive action of nrp1a must not exceed a certain
threshold in order for MN development to proceed nor-
mally, which is ensured by the transcriptional repression by
HIF1-E2F7.
Although VEGFA regulates neuronal development (34),
and is regulated byHIF1 (3) and E2F7/8 (14), were are con-
fident that regulation of VEGFA by HIF1 or E2F7/8 does
not affect the observed MN phenotype for several reasons.
First, we used a e2F7/8MO concentration (5 ng each) that
did not significantly affect vegfAa expression and angio-
genesis as previsouly shown (14). Second, others reported
that MO depletion of vegfa in zebrafish abolished angio-
genesis, but did not disturb ventral MN guidance (43), and
that reduced neuronal Vegfa expression in mice also did not
disturb MN guidance during embryogenesis, although it
did cause late-onset progressive degeneration of lower mo-
tor neurons after 5 months of age (44). Therefore, we con-
clude that the regulation of MN guidance by HIF1-E2F7
does not implicate VEGFA, but is at least partially depen-
dent on NRP1, as the MN defects are partly rescued in
nrp1ahu10012 mutant fish (Figure 6A and B). In this light it
is interesting to mention that MO-inhibition of hif1 both
derepressed nrp1a and nrp1b expression in hypoxic zebrafish
embryos (Supplementary Figure S5), suggesting that the
HIF1-E2F7 complex may control MN development also
through nrp1b.
Because e2f7/8 double mutant fish (e2f7A207/A207;
e2f8A196/A196) phenocopy angiogenic defects induced by
e2f7/8 MO (14), we next analyzed if these e2f7/8 mutant
zebrafish also phenocopy the MN defects. Because deletion
of either E2F7/8 or HIF1 alone deregulates NRP1
expression in vitro (Figures 2D and 4D) and in vivo (Figures
4F and 5A), it can be expected that mutation of e2f7/8 in
zebrafish is sufficient to cause a MN defect. At 48 hpf, ap-
proximately 5% of 137 analyzed wildtype Tg(nrp1a:gfp)js12
zebrafish displayed a MN defect. Notably, similar MN
analysis of 220 embryos obtained by crossing e2f7−/−;
e2f8−/− with e2f7−/−; e2f8+/− Tg(nrp1a:gfp)js12 zebrafish,
revealed that these embryos displayed significantly more
MN defects (∼20%) compared to wild-type embryos
(Figure 6C). Sequencing of the e2f7/8 mutant embryos
revealed that the MN defect occurred both in e2f7/8
double knockout (DKO) embryos (e2f7−/−; e2f8−/−) and
in e2f7−/−; e2f8+/− zebrafish (Supplementary Figure S6B),
although the phenotype was significantly enhanced in
DKO compared to e2f7−/−; e2f8+/− embryos (58.6% versus
41.4%, P < 0.05). This is consistent with the enhanced
occurrence of angiogenic defects in e2f7/8DKO, compared
to e2f7−/−; e2f8+/− embryos (14). Sequencing of embryos




















































































































































Figure 6. The HIF1-E2F7 complex regulates MN development in an NRP1-dependent manner. (A) Confocal images of MN in the trunk regions above
the yolk sac extension of Tg(nrp1a:gfp)js12 zebrafish at 48 hpf. Zebrafish embryos were non-injected (NIC: non-injected control), or injected with e2f7/8 (5
+ 5 ng), hif1ab (5 ng), or control (10 ng) MO. Stunted MN are indicated with an asterisks, truncations resulting in the absence of the hinge are indicated
with an arrow. Black bar presents 50 M. (B) Quantification of MN defects in all MN analyzed, as described under (A). Left graph shows quantification
of MN defects in e2f7/8 MO or hif1ab MO injected or non-injected wild-type Tg (nrp1a:gfp)js12 zebrafish. The two right graphs show quantification of
MN defects in e2f7/8 MO or hif1ab MO injected, and non-injected wild-type (black bars) or nrp1ahu10012 mutant (white bars) Tg(nrp1a:gfp)js12 zebrafish.
The numbers in the graphs present the number of analyzed zebrafish (obtained from at least three independent experiments). Per fish, all MN above the
yolk sac extension (10–11 MN) were analyzed. (C) Analysis of MN defects in wild-type Tg(nrp1a:gfp)js12 zebrafish embryos, or in embryos obtained from
crossing e2f7A207/A207; e2f8A196/A196; Tg(nrp1a:gfp)js12 zebrafish with e2f7A207/A207; e2f8WT/A196; Tg(nrp1a:gfp)js12 zebrafish. MN defects were analyzed in
the trunk regions above the yolk sac extension at 48 hpf. Left panels show representative confocal images of analyzedMN for both groups. Graph presents
quantification of the number of fish with MN defects (presented as%), analyzed in 137 wild-type, or 220 e2f7/8 mutant zebrafish embryos. All quantified
data present the average ± S.E.M. compared to the indicated controls in at least three independent experiments. *P < 0.01, **P < 0.001, ***P < 0.0001.
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derived from e2f7−/−; e2f8+/− intercrosses did not reveal
a significant defect in e2f7−/−; e2f8+/+ embryos, showing
that two wild-type alleles of e2f8 can compensate for the
loss of e2f7 (data not shown). In conclusion, our data
show that e2f7/8 mutant zebrafish phenocopy the e2f7/8
MO-induced MN phenotype, and demonstrate that the
HIF1-E2F7/8 complex regulates guiding of ventral
MN during zebrafish development at least partially in an
NRP1-dependent manner.
DISCUSSION
By performing ChIP-seq we have identified the existence of
a HIF1-E2F7 co-regulated transcriptional network con-
sisting of 2258 target genes, although the majority of these
targets are not or only marginally regulated in HeLa cells,
or during normal proliferation. By combining our ChIP-
seq data with microarray analysis we have identified 18 di-
rect transcriptionally controlled HIF1-E2F7 targets (Fig-
ure 2D), using a cut-off of ≥ 2 fold change regulation and
a P-value of <0.05 in the microarrays (or 56 targets using
a cut-off of ≥1.5-fold change and a P-value of <0.05; S2F
Figure). Notably, these combined data, as well as the mi-
croarray data alone (Supplementary Figure S2C,D) demon-
strate the almost complete lack of differential regulation
of common targets (knowing that HIF1 is defined as an
activator, and E2F7 as a repressor), excluding that HIF1
and E2F7 act independent on a common set of promot-
ers, at the same time providing clear evidence for the exis-
tence of the HIF1-E2F7 transcription complex. Interest-
ingly, gene-ontology analysis identified many HIF1-E2F7
regulated biological processes (Supplementary data set S3),
suggesting versatile yet unexplored functions of the com-
plex.
In our ChIP-seq experiments we identify more E2F7 tar-
gets (2381) compared to our previous study (737) (20). Al-
though the methodology was similar, here we used non-
synchronized, rather than S-phase synchronized cells, and
used 4 timesmore ChIP input material, allowing the discov-
ery of a wider array of targets. The large amount of HIF1
ChIP-seq targets identified in this study is comparable to a
previous study where 7704 HIF1 target genes were iden-
tified in T cells (45), although another study identified 356
high-stringencyHIF1-binding sites inMCF-7 breast cancer
cells (27). These differences may be explained by alternative
technical approach.
The large number of HIF1 binding targets identified in
this and another study (45), suggest that HIF1 may serve
a general role in regulating gene expression in response to
hypoxia.With respect to this it is interesting tomention that
the HIF binding motif 5′-RCGTG-3′overlaps with the E-
box motif 5′-CACGTG-3′ to which MYC binds, a factor
which has been reported to accumulate on all active pro-
moters, amplifying the output of the existing gene expres-
sion (46). Because HIF1 is capable of replacing MYC from
promoters (47), it is tempting to speculate that HIF1 could
counteract MYC in hypoxia, inhibiting the overall gene ex-
pression. Consistently, HIF1 is indeed required for the re-
ported hypoxia-induced cell cycle arrest in response to O2-
deprivation (48). Furthermore, the HIF1-E2F7 complex
could play a particular role in the hypoxia-induced cell cy-
cle arrest as E2F7 may recruit HIF1 to classic E2F targets
involved in cell cycle progression.
Although HIF factors generally function as activators
(27,28) and E2F7/8 as repressors (20), here we provide ev-
idence that the HIF1 -E2F7 complex can have both tran-
scriptional properties (Figure 7). These properties are at
least in part determined by the presence of E2F or HIF
bindingmotifs present in the common target promoters, be-
cause we show that E2F7 engages HIF in transcriptional
repression of NRP1 by acting directly on a 41-bp promoter
region that contains 5 E2F, but no HIF motifs. HIF on the
other hand can engage E2F7 in transcriptional activation,
as we previously showed for VEGFA, acting independent
of consensus E2F motifs, but dependent on a HIF motif
(14). In line with these results, ChIP-seq experiments for
E2F1, 4 and 6 showed that the majority of their target re-
gions do not contain the E2F motifs, as previously men-
tioned (20), suggesting that the recruitment of E2Fs to E2F
motif-less regions can indeed be performed by other tran-
scription factors, such as nuclear factor– (NF–),MYC
and CAAT enhancer/binding protein– (CEBP) (6). We
identified HIF1 as such a factor, an also show that HIF1
instead can be recruited to the HIF motif-less NRP1 pro-
moter by E2F7.
In this study we demonstrate a hypoxia-specific role for
E2F7, by showing that specifically E2F7 expression is in-
duced byHIF1 in hypoxia (Figure 1, Supplementary Figure
S1). In addition, our input-corrected ChIP-qPCR experi-
ments demonstrate a comparable or sometimes increased
E2F7 binding to the common targets in hypoxia (Figures
3A, C and 4B), whereas E2F7 binding to the classic E2F
targets E2F1 and E2F3 was reduced (Figure 3E). Further-
more, by analyzing mRNA expression of the HIF1-E2F7
repressed targets we reveal that these genes are more sig-
nificantly repressed by E2F7 in hypoxia (Figures 3B and
4D, Supplementary Figure S4A). Therefore, we conclude
that the increased E2F7 expression in hypoxia results in en-
hanced downregulation of the HIF1-E2F7 repressed tar-
gets.
Mechanistically, the HIF1-E2F7 complex may repress
the hypoxia downregulated targets by replacing the activa-
tor E2F1 from their promoters, as we observed a reversed
correlation between the binding of HIF1 and E2F1 to
these promoters (Figures 3A and 4B), and a repression of
E2F1-inducedNRP1 reporter activity by E2F7 and HIF1
(Figure 5H, K). Interestingly, others reported that E2F1
and E2F7 can form a heterodimeric complex on the DNA
through binding to adjacent E2F motifs, in which E2F7
binding eventually leads to the dissociation of E2F1 from
the promoter, switching the promoter from active to inac-
tive (49). Thus the initial E2F1 binding to the E2F-hub in
theNRP1 promoter, may recruit the HIF1-E2F7 complex
to adjacent E2F motifs, leading to the dissociation of E2F1
from the promoter (Figure 7), a mechanism that could be
relevant for all common repressed targets. However, the reg-
ulation of NRP1 may be more complex, involving other
E2F family members, as analysis of existing ChIP-seq data
also showed binding of E2F4 and 6 to the same NRP1 pro-
moter region (Supplementary Figure S7).
Interestingly, several studies have observed a downreg-
ulation of Neuropilin gene expression in response to hy-
























Figure 7. Dualistic functions of the HIF1-E2F7 complex in gene regulation, and biological implications. Hypoxia induces E2F7 expression through tran-
scriptional activation by HIF1. The almost complete absence of differential gene regulation of common targets by the classified transcriptional activator
HIF1 and the repressor E2F7, as observed in our microarray data (Supplementary Figure S2C and D), as well as in the combined ChIP-seq and mi-
croarray data (Figure 2C and D; Supplementary Figure S2F), unequivocally demonstrated the existence of the transcriptional network regulated by the
HIF1-E2F7 complex, in which the complex can either function as a repressor or activator. We reveal a direct role for HIF1 in transcriptional repression
by acting independent of HIF-binding sites, but instead through an E2F-hub, as we show for NRP1. We expect that the HIF1-E2F7 complex stimulates
gene expression throughHIF-binding sites, as we recently showed forVEGFA (14). Although not shown,NRP1 is also repressed, andCYR61 stimulated by
HIF1/ARNT (Supplementary Figure S4B,C). The HIF1-E2F7 complex may counterbalance the expression of common repressed targets by replacing
E2F1 from these promoters in hypoxia, when expression of HIF1 and E2F7 is induced. This mechanism regulates MN axon guidance during normal
development, but could also serve neuroprotective functions, as growth cone collapse may eventually result in neuronal death. Whether HIF1-E2F7 induc-
tion of VEGFA expression also serves neuroprotective functions remains to be shown, which is also true for the potential role of the HIF1-E2F7/NRP1
pathway in regulating (tumor) angiogenesis.
poxia. Hypoxic repression of NRP1 has been reported in
human astrocytoma cells (50), and in bone marrow de-
rivedmacrophages (51), while hypoxicNRP2 repression has
been observed in glioblastoma and melanoma cells (52).
Although ectopic HIF1 levels could reduce NRP2 pro-
moter activity in glioblastoma cells (52), and hypoxic Nrp1
mRNA expression in macrophages was suggested to be me-
diated through activation of the NF-B pathway down-
stream of HIF2 (51), the exact molecular mechanism of
how Neuropilin genes are repressed by hypoxia has so far
remained elusive. Our data now demonstrate that E2F7 en-
gages HIF1 in direct transcriptional repression of NRP1
in hypoxia, acting independent of HIF-binding sites, but in-
stead through an ‘E2F-binding site hub’ located in the prox-
imal NRP1 promoter region. Thus, providing evidence for
a molecular mechanism of how expression of NRP genes is
repressed by hypoxia.
Here, we report that regulation of NRP1 by the HIF1-
E2F7 complex is essential for axon guidance of spinal MN
during zebrafish development, also providing evidence for
a novel role for E2Fs in the regulation of neuronal devel-
opment through the direct transcriptional control of atyp-
ical E2Fs targets (see introduction). Notably, the relatively
minor MN phenotype observed in e2f7/8mutant zebrafish
may be explained by the fact that other E2F proteins may
compensate for the loss of E2F7/8. For example, the E2F
repressors E2F4 and E2F6 were also observed to bind the
NRP1 promoter (Supplementary Figure S7). The identi-
fication of NRP1 as a target of the E2F and HIF path-
ways provides a novel mechanism of how these pathways
may mediate vascular and neuronal development, whereas
their deregulation may contribute to neurodegenerative dis-
eases and cancer (Figure 7). With respect to neuronal de-
velopment it has recently been put forward that transcrip-
tional regulation of neuropilins presents a significantmolec-
ular mechanism in control of axon guidance (35). Our data
identify the HIF and E2F pathways as novel and essen-
tial players in this process. In neurodegenerative diseases
the HIF1-E2F7 complex may have neuroprotective func-
tions by inhibiting E2F-induced (NRP1-dependent) neu-
ronal death, e.g. in response to cerebral ischemia (38). In
this respect it is interesting to mention that inactivation of
E2F7/8 in zebrafish andmice results in widespread apopto-
sis, including neuronal tissues (7,14). In mice, this cell death
phenotype of E2f7/8 deficient mice could be rescued upon
additional deletion of E2f1 (7), providing further support
that the balance of transcriptional activity between the ac-
tivator E2F1, and the repressor HIF1-E2F7 complex may
be critical for the survival and development of neuronal
cells. Interestingly, the HIF1-E2F7 complex may also be
involved in amyotrophic lateral sclerosis (ALS), a neurode-
generative MN disease characterized by progressive distal
axonopathy that precedes actual motor neuron death. No-
tably, deletion of theHIF-responsive element in theVEGFA
promoter in mice results in late-onset (>5 months) progres-
sive degeneration of lowermotor neurons, indicative ofALS
(44). Adaptation to hypoxia is indeed crucial for MN as
they are extremely susceptible to ischemia (53). Deregula-
tion of axon guidance proteins has been proposed as a ma-
jor cause of ALS (54), as was recently also suggested for
SEMA3A/NRP1 signaling in a mouse model for ALS (55).
Therefore, deregulation of VEGFA (14) and NRP1 (this
study) by the cooperative action of HIF1 and E2F7 may
be implicated in ALS.
Deregulation of HIF1-E2F7/NRP1 pathway may also
be involved in cancer. For example, as part of a VEGR
signaling complex through which NRPs stimulate tumor
angiogenesis (33). Increased activator E2F activity, as de-
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tected in a variety of human cancers (6), may thus promote
tumor angiogenesis through stimulation of NRP1 expres-
sion. In addition, HIF1 and E2F7mediatedNRP1 expres-
sionmay also affect tumor vascularization and immunity by
regulating the NRP1-dependent tumor infiltration capac-
ity of macrophages and regulatory T cells (51,56). Interest-
ingly, hypoxia-induced downregulation ofNRP1 expression
in tumor infiltrating macrophages, caused their retention
in hypoxic tumor areas (51), suggesting that the HIF1-
E2F7/NRP1 pathway may be responsible for the homing
of tumor associated macrophages towards hypoxic tumor
regions. For these reasons it will be interesting to investi-
gate the role of the novel HIF1-E2F7/NRP1 pathway not
only in neurodegenerative diseases, but also in cancer.
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